Click or tap the video thumbnail to play the video
Sarah Stanley, an infectious disease expert at UC Berkeley’s School of Public Health, normally researches tuberculosis in her lab. But when the COVID-19 pandemic shut down all normal research operations on campus, she quickly utilized her own discretionary funds to mobilize her lab and student researchers to study the SARS-CoV-2 live virus.
A partnership with Julia Schaletzky, Executive Director of Berkeley’s Center for Emerging and Neglected Diseases, has allowed Stanley’s lab to test whether pre-existing, FDA approved drugs would have any effect on killing the virus.